Byetta
Byetta, manufactured by Amylin Pharmaceuticals, is an injectable GLP-1 therapy used to treat type 2 diabetes. The drug acts upon the pancreas, stimulating it to make more insulin. Unfortunately, Byetta doubles an individual’s risk of developing pancreatitis, and also puts patients at increased risk for kidney damage and kidney failure.
If you or a loved one have taken Byetta and have experienced pancreatic or kidney problems, you may be eligible to join lawsuits that are underway. We invite you to familiarize yourself with the content on our website, and then contact one of our attorneys to discuss your case. Each case is unique, and only by speaking to an experienced attorney will you get the answers you are looking for.
Blog Posts
Incretin Mimetic Drug Lawsuits Consolidated in Federal Court
On August 28, 2013, it was announced that litigation involving incretin mimetic drugs Byetta, Victoza, Januvia, and Janumet are being consolidated into multi-district litigation in California federal court. Usually lawsuits against different companies, as is in this case, are not consolidated into one MDL. In this case however, many of the plaintiffs bringing the lawsuits…
Medical Journal Links Byetta, Januvia to Pancreatitis, Pancreatic Cancer, and Thyroid Cancer
After reviewing the data from the adverse events reported to the FDA, researchers found that there was a six-fold increase in association between pancreatitis and Byetta and Januvia. These results were published in the medical journal Gastroenterology. The scientists found other associations as well, including a threefold increase in pancreatic cancer, and a four-fold increase…
Timeline of FDA Action: Byetta
Byetta is a GLP-1 agonist injection manufactured by Amylin Pharmaceuticals, Inc. It was approved by the FDA in 2005. Its generic name is exenatide. Byetta is administered twice daily by injection, but also comes in a once-weekly form called Bydureon. Byetta works by forcing the pancreas to increase insulin production and to suppress release of…
